China Biotech Services Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	6.9yrs

Son yönetim güncellemeleri

Recent updates

China Biotech Services Holdings Limited's (HKG:8037) 28% Share Price Plunge Could Signal Some Risk

Aug 12

Some Shareholders Feeling Restless Over China Biotech Services Holdings Limited's (HKG:8037) P/S Ratio

Jun 26

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Mar 07

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

Jan 18

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Jan 06

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Dec 09

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Aug 24

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Nov 05

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Oct 13

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Jun 28

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

Mar 16

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Dec 01

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Jul 26

China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Apr 05

Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Mar 23

Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Feb 23

Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

Jan 28

What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

Jan 11

The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Dec 08

CEO

China Biotech Services Holdings CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiaolin Liu	Executive Chairman & Compliance Officer	7.3yrs	HK$5.01m	54.38% HK$ 244.1m
Song Huang	CTO & Executive Director	4.9yrs	HK$580.00k	Veri yok
Xun He	Executive Director	no data	HK$1.06m	0% HK$ 0
Xuanming Yang	Chief Scientific Officer	no data	Veri yok	Veri yok
Yi Yao	Consultant	3.5yrs	HK$1.70m	Veri yok
Miu Shun Wong	Company Secretary	7.1yrs	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: 8037 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiaolin Liu	Executive Chairman & Compliance Officer	7.3yrs	HK$5.01m	54.38% HK$ 244.1m
Song Huang	CTO & Executive Director	7.2yrs	HK$580.00k	Veri yok
Xun He	Executive Director	6.3yrs	HK$1.06m	0% HK$ 0
Ting Yuk Wu	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Guoxiang Yan	Independent Non-Executive Director	7.3yrs	HK$240.00k	Veri yok
Hongji Qian	Independent Non-Executive Director	6.7yrs	HK$240.00k	Veri yok
Gang Song	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Paul Waring	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yang Xin Fu	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Yao Shiego	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Shengli Bi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yuantao Guo	Independent Non Executive Director	less than a year	Veri yok	Veri yok

6.9yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 8037 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.9 yıldır).

China Biotech Services Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

China Biotech Services Holdings Limited Announces Resignation of Chui Hoi Yam as Non-Executive Director

China Biotech Services Holdings Limited Elects Guo Yuantao as an Independent Non-Executive Director

China Biotech Services Holdings Limited, Annual General Meeting, Jun 06, 2024

Executive Chairman & Compliance Officer recently bought HK$64k worth of stock

Executive Chairman & Compliance Officer recently bought HK$105k worth of stock

Executive Chairman & Compliance Officer recently bought HK$105k worth of stock

Recent updates

First half 2024 earnings released: HK$0.083 loss per share (vs HK$0.032 loss in 1H 2023)

China Biotech Services Holdings Limited's (HKG:8037) 28% Share Price Plunge Could Signal Some Risk

China Biotech Services Holdings Limited to Report Q2, 2024 Results on Aug 26, 2024

Some Shareholders Feeling Restless Over China Biotech Services Holdings Limited's (HKG:8037) P/S Ratio

China Biotech Services Holdings Limited Announces Resignation of Chui Hoi Yam as Non-Executive Director

China Biotech Services Holdings Limited Elects Guo Yuantao as an Independent Non-Executive Director

China Biotech Services Holdings Limited Announces the Results of the Phase I Clinical Study of LY007 Cellular Injection

China Biotech Services Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.27 profit in FY 2022)

China Biotech Services Holdings Limited announced that it expects to receive HKD 88 million in funding

China Biotech Services Holdings Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

New major risk - Share price stability

Pengbo (Hainan) Medical Technology Co., Ltd. Announces the Approval by the Hainan Provincial Medical Products Administration

Executive Chairman & Compliance Officer recently bought HK$64k worth of stock

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Third quarter 2023 earnings released: HK$0.037 loss per share (vs HK$0.17 profit in 3Q 2022)

China Biotech Services Holdings Limited to Report Q3, 2023 Results on Nov 13, 2023

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Second quarter 2023 earnings released: HK$0.016 loss per share (vs HK$0.11 profit in 2Q 2022)

New minor risk - Share price stability

China Biotech Services Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

China Biotech Services Holdings Limited to Report First Half, 2023 Results on Aug 11, 2023

New minor risk - Market cap size

Executive Chairman & Compliance Officer recently bought HK$105k worth of stock

Executive Chairman & Compliance Officer recently bought HK$105k worth of stock

China Biotech Services Holdings Limited Announces Redesignation of Chui Hoi Yam from an Executive Director to Non-Executive Director

Executive Chairman & Compliance Officer recently bought HK$139k worth of stock

China Biotech Services Holdings Limited Declares Final Dividend for the Year Ended 31 December 2022

First quarter 2023 earnings released: HK$0.016 loss per share (vs HK$0.036 profit in 1Q 2022)

Upcoming dividend of HK$0.01 per share at 1.0% yield

Full year 2022 earnings released: EPS: HK$0.27 (vs HK$0.02 in FY 2021)

Investor sentiment improves as stock rises 22%

China Biotech Services Holdings Limited announced that it expects to receive HKD 77.8 million in funding from Guoyuan Securities Investment (Hong Kong) Limited

China Biotech Services Holdings Limited Announces Board Changes

Less than half of directors are independent

China Biotech Services Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Nine Months Ended 30 September 2022

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

China Biotech Services Holdings Limited to Report Q3, 2022 Results on Nov 14, 2022

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Second quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.023 in 2Q 2021)

China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

China Biotech Services Holdings Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment deteriorated over the past week

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Investor sentiment improved over the past week

China Biotech Services Holdings Limited Announces Management Changes

China Biotech Services Holdings Limited, Annual General Meeting, Jun 20, 2022

First quarter 2022 earnings released: EPS: HK$0.036 (vs HK$0.002 in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: EPS: HK$0.02 (vs HK$0.031 in FY 2020)

Investor sentiment improved over the past week

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

China Biotech Services Holdings Limited Announces Completion of First Patient Enrollment in Phase I Clinical Trial for Treatment of Relapsed/Refractory CD20-Positive B-Cellnon-Hodgkin Lymphoma

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS HK$0.003 (vs HK$0.064 in 3Q 2020)

Second quarter 2021 earnings released: EPS HK$0.023 (vs HK$0.019 loss in 2Q 2020)

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Insider recently bought HK$44m worth of stock

Investor sentiment improved over the past week

Compliance Officer & Executive Director has left the company

First quarter 2021 earnings released: EPS HK$2.00 (vs HK$0.023 loss in 1Q 2020)

Investor sentiment improved over the past week